Zi-Factor, 250 mg capsules 6 pcs

Zi Factor is antibacterial.

When creating high concentrations in the focus of inflammation it has a bactericidal effect.

Pharmacodynamics

The spectrum of action is broad and includes Gram-positive cocci: Streptococcus pneumoniae, Streptococcus pyogenes, Streptococcus agalactiae, Streptococcus groups CF and G, Staphylococcus aureus, Staphylococcus viridans, Gram-negative bacteria Haemophilus influenzae, Moraxella catarrhalis, Bordetella pertussis, Bordetella parapertussis, Legionella pneumophila, H. ducreyi, Campylobacter jejuni, Neisseria gonorrhoeae, Gardnerella vaginalis, some anaerobic microorganisms: Bacteroides bivius, Clostridium perfringens, Peptostreptococcus spp, as well as Chlamydia trachomatis, Mycoplasma pneumoniae, Ureaplasma urealyticum, Treponema pallidum, Borrelia burgdorferi. It is inactive against Gram-positive bacteria resistant to erythromycin.

Pharmacokinetics

Stable in acidic environment, lipophilic, rapidly absorbed in the gastrointestinal tract. After oral administration in a dose of 500 mg, Cmax in plasma is 0.4 mg/L and is reached after 2.5-2.96 hours. Bioavailability is 37%. It penetrates well into the respiratory tract, organs and tissues of the urogenital tract (in particular the prostate gland), skin and soft tissues.

The concentration in tissues and cells is 10-50 times higher than in plasma, and in foci of infection 24-34% higher than in healthy tissues (correlates with the degree of inflammatory edema). It is transported by phagocytes to the focus of infection, where it is released during phagocytosis. The apparent volume of distribution is 31.1 l/kg.

The high antibacterial level is maintained in the focus of inflammation for 5-7 days. It is metabolized in the liver by demethylation to form inactive metabolites.

Extraction occurs in 2 stages; T1/2 is 14-20 h (between 8-24 h after drug administration) and 41 h (between 24-72 h).

Indications

Infections of the upper (pharyngitis, tonsillitis) and lower (bacterial and atypical pneumonia, bronchitis) airways, ENT organs (otitis media, sinusitis), skin and soft tissue (rye, impetigo, secondary infected dermatoses), urogenital tract (uncomplicated urethritis and/or cervicitis), Lyme disease (treatment of erythema migrans), diseases of the stomach and duodenum associated with Helicobacter pylori (in combination therapy).

Active ingredient

Composition

Affective ingredient:

azithromycin dihydrate (in terms of azithromycin) 250 mg;

Ancillary substances:

Milk sugar;

Corn starch;

Aerosil;

How to take, the dosage

Overly, 1 hour before or 2 hours after meals once a day.

In adults with upper and lower respiratory tract infections – 500 mg/day for 3 days (cumulative dose – 1500 mg);

Therapeutic use In case of infections of skin and soft tissue – 1000 mg/day for the first day, afterwards (days 2-5) 500 mg/day (cumulative dose – 3000 mg);

In acute infections of the urogenital tract (uncomplicated urethritis or cervicitis) – 1000 mg once;

In Lyme disease (initial stage treatment – erythema migrans) – 1000 mg/day on the first day, further (days 2-5) – 500 mg/day (a course dose of 3000 mg); in peptic ulcer associated with Helicobacter pylori – 1000 mg/day for 3 days in combination therapy. In children – 10 mg/kg of body weight during 3 days or 10 mg/kg during the first day and then 5 mg/kg/day during 4 days (the course dose – 30 mg/kg), in erythema migrans treatment – 20 mg/kg during the first day, further (days 2-5) – 10 mg/kg.

Interaction

Antacids (aluminum and magnesium-containing), ethanol, and food slow down and decrease absorption.

Increases digoxin concentration, slows excretion and increases plasma concentration and toxicity of cyclosporine, indirect anticoagulants, methylprednisolone, felodipine, carbamazepine, terfenadine, hexobarbital, ergot alkaloids, valproic acid, disopyramide, bromocriptine, phenytoin, oral hypoglycemic agents, theophylline and other xanthine derivatives.

Lincosamides impair efficacy, tetracycline and chloramphenicol enhance it. Pharmaceutically incompatible with heparin.

Contraindications

Hypersensitivity (including to other macrolides), hepatic and/or renal failure, breastfeeding, infants under 1 year of age.

Side effects

Nervous system and sensory organs: ≤1% – dizziness, headache, somnolence; in children – hyperkinesia, anxiety, neurosis, sleep disorders.

Cardiovascular system and blood (hematopoiesis, hemostasis): ≤1% – palpitation, pain in the chest.

Gastrointestinal system disorders: diarrhea (5%), nausea, abdominal pain (3%); ≤1% – dyspepsia, flatulence, vomiting, melena, cholestatic jaundice, increased liver transaminases activity; in children – constipation, anorexia, gastritis.

Urogenital system disorders: ≤1% – vaginal candidiasis, nephritis.

Allergic reactions: rash, photosensitization, Quincke’s edema.

Other: increased fatigue, in children – conjunctivitis, itching, urticaria.

Overdose

Symptoms: severe nausea, temporary hearing loss, vomiting, diarrhea.

Pregnancy use

Possible if the expected effect of therapy exceeds the potential risk to the fetus.

Breastfeeding should be stopped during treatment.

Similarities